Please assess the completion status of the following clinical trial:

Trial Title: Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult female volunteers, 18 to 45 years of age, who have signed an informed consent form following a detailed written explanation of participation in the protocol.~* Volunteers who are in good health as determined by medical history, physical examination and clinical judgement.~* Available for the duration of the study.~* Women who, if capable of becoming pregnant during the study, have agreed to have a pregnancy test immediately before immunisation, and to use appropriate contraception methods during the whole study period. Appropriate contraception shall include physician-prescribed oral hormonal agents, barrier contraceptives, regular and consistent use of condoms without spermicidal agents, or intrauterine devices only.~* Agree not to undertake any vaginal practices other than receptive intercourse with a male or use of sanitary tampons during menses. Use of condoms without spermicidal agents is encouraged.~* Have not donated blood during 3 months prior to study entry and agree to not donate for 3 months after the end of their participation in the study~Exclusion Criteria:~* They have hypersensitivity to any component of the vaccine used in this study.~* They are found to be HIV antibody or HIV proviral DNA positive at the time of initial screening.~* They have a known or suspected history of cervico-vaginal disease, malignancy or abnormality discovered at time of screening, or who have undergone a Letts procedure.~* They present in the samples obtained at the screening visit:~* a clinically significant abnormality in the haematological or biochemical assays.~* Positive tests for Hepatitis B and/or C infection~* Positive tests for genital infections: Chlamydia trachomatis, Neisseria gonorrhoea, Treponema pallidum (syphilis).~* An abnormal value will be defined by the ranges quoted by pathology laboratory.~* They have a known or suspected impairment of lung, heart, liver, kidney, blood disorders or immune dysfunction.~* They are receiving immunosuppressive therapy (including systemic steroids).~* They are receiving any regular medications via vaginal route.~* They have any acute infections (including fever greater than or equal to 38°C) or any chronic disease.~* They present a current problem with substance abuse or with a history of substance abuse, which, in the opinion of the investigator, might interfere with participation in the study.~* They have any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.~* They have received an investigational agent within 3 months prior to study entry.~* They cannot speak fluent English~* They are planning to leave the area of the study site prior to the end of the study period, or are likely not to complete the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Vaginal immunisation (Type: EXPERIMENTAL): CN54gp140 glycoprotein-hsp70 conjugate vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete